Considering these findings, SGLT2 inhibitors are being considered as a promising adjunct in the management of OSA, especially in patients with obesity, type 2 diabetes, or heart failure, though dedicated trials are needed to confirm direct benefits on OSA severity and clinical outcomes [106]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.